ATAI Life Sciences (“ATAI” or the “Company”), a global biotechnology company builder founded by Christian Angermayer that envisions an end to mental illnesses, today announced the close of a $24 million convertible note financing round. Despite market turmoil caused by the COVID-19 pandemic, the round saw strong support from both new and existing investors.
ATAI Life Sciences announces close of $24 million convertible note financing round and welcomes Jason Camm of Thiel Capital to Board of Directors
April 23, 2020
Articles
12:30 pm
JOIN OUR MAILING LIST
Sign up to receive the latest news on atai.
Email